Obinutuzumab active in three types of lymphoma Healio Thirty-eight patients had undergone prior treatment with rituximab (Rituxan, Genentech/Idec Pharmaceuticals) and 22 were rituximab refractory. Researchers assigned the patients to one of two regimens. The first group received 400 mg obinutuzumab on ... |
